Neurocrine Biosciences, Inc.9 mg/d (4.

diseases tourette

Live Audio Webcast Tuesday, April 5, 2005

SAN DIEGO, Neurocrine Biosciences, Inc. The study was conducted in adults only.

alzheimer normal

A replay will become available approximately three hours
after the live event concludes. Food and Drug Administration (FDA) in the near future.

parkinson proprioception

com or via a link provided by
CIBC World Markets at
http://www.com/webcasts /cibcwm/biotech05/12207129. Frucht, MD, Assistant Professor of
Neurology, Neurological Institute of New York, Columbia University
Medical, Center for Parkinson's Disease and Other Movement Disorders ,
and lead investigator of the study.
Twenty-eight patients (93%) had tried other medications without
adequate relief prior to being placed on tetrabenazine.
Prestwick was granted both fast track and orphan designation by the
FDA for tetrabenazine.

sclerosis timer

Neurocrine Biosciences to Present at the CIBC Biotechnology + Specialty Pharmaceuticals Conference

com

9 mg/kg/d)
for 1.

proprioception tourette

Twenty -two of the 30 patients (73%) experienced a reduction in
movements (as assessed by the examining physician ) after starting
tetrabenazine.

parkinson injuries

measures sclerosis

news releases are available through the Company's
website via the Internet at http://www.

New Data Reported on Tetrabenazine for the Treatment of Pediatric Hyperkinetic Movement Disorders

Prestwick Pharmaceuticals

Prestwick Pharmaceuticals, Inc.
In October 2004, Prestwick announced the results of its Phase III
study of tetrabenazine for chorea associated with Huntington's
Disease.

pill alarms

A retrospective chart review was conducted to assess the efficacy
and tolerability of tetrabenazine among these patient populations. Side
effects, which were ameliorated with a reduction in dose, were
experienced in nineteen patients (63%), including sedation (30%),
behavioral changes (20%), depression (10%), worsening of movements
(6%), nausea (3%) and parkinsonism (3%). To date, the company has in-licensed rights
relating to product candidates in clinical development for the
treatment of CNS disorders, including chorea associated with
Huntington 's Disease, Parkinson's disease and schizophrenia.

normal injuries

veracast. is a product-based biopharmaceutical company
focused on neurological and endocrine diseases and disorders. The study was approved by the
medical center's institutional review board, and neither the study nor
the investigators were supported by Prestwick. is a product-focused specialty
pharmaceutical company engaged in the development and
commercialization of drugs with high commercial potential and
relatively low development risk that target chronic diseases of the
central nervous system.

wrist neurological

"We are encouraged by the fact
that nearly three quarters of children treated with tetrabenazine
experienced a reduction in their involuntary movements.

load disorders

On average,
patients were treated with a total dose of 150.

sclerosis measured

neurocrine.

Pharmaceutical Writers/Business Editors

MIAMI BEACH, Fla.

neurological proprioception

S.

measures trauma

tourette disorders

Nine patients (30%)
discontinued tetrabenazine due to behavior changes (3 ), sedation (3),
worsening or lack of improvement in movements (2) and major depression
(1)."

Tetrabenazine

Tetrabenazine is available in some European markets and Australia
as XENAZINE (R) and in Canada as NITOMAN(R) for the treatment of
hyperkinetic movement disorders.

neurological nutritional

Our product
candidates address some of the largest pharmaceutical markets in the world
including insomnia , anxiety, depression, diabetes, multiple sclerosis,
irritable bowel syndrome, eating disorders, pain , and autoimmunity. Side effects can include drowsiness,
insomnia, akathisia and depression.

stroke diseases

"This is one of the largest reported studies of children treated
with tetrabenazine," said Steven J.

normal alarms

"

Study Design and Results

Over the course of 18 years, 30 children aged 18 years and younger
were treated with tetrabenazine at Columbia University Medical Center
for a variety of hyperkinetic movement disorders, including chorea,
dystonia, and Tourette Syndrome or tics.3 years.

diseases parkinson

"The results of this pediatric study support earlier findings in
adults that suggest tetrabenazine may be an effective and
well-tolerated treatment option for severe pediatric hyperkinetic
movement disorders," said Dr.

load normal

Sixteen patients continued tetrabenazine along with at
least one other medication to control movements, while movements were
sufficiently controlled with tetrabenazine alone in six patients. "Similarly, side effects were
typically dose-dependent, and we did not observe tardive dyskinesia in
our patient population.

alzheimer curves

neurocrine. Viewers are encouraged to visit the website
approximately 5 minutes prior to the presentation to download or install any
necessary software.

injuries curves

The presentation will be simultaneously webcast and can be accessed on
the Company's website at http://www. The presentation will be archived until Tuesday, April 19,
2005.

proprioception headache

(Nasdaq: NBIX) announced today that the Company will present at the CIBC
Biotechnology and Specialty Pharmaceuticals Conference on Tuesday, April 5,
2005 at 11:30AM Eastern Daylight Time (EDT) / 8:30AM Pacific Daylight Time
(PDT).cfm
Gary Lyons, President and Chief Executive Officer of Neurocrine will
present an overview of the Company and provide an update on Neurocrine's broad
development pipeline and research programs.
If you are unable to attend the webcast and would like further information
on this announcement please contact the Investor Relations Department at
Neurocrine Biosciences at (858) 617-7600 and ask for Claudia Jones or
Elizabeth Foster. Tetrabenazine is not FDA-approved for
marketing in the United States. The company
anticipates filing a New Drug Application (NDA) for tetrabenazine with
the U.

proprioception tourette

Neurocrine Biosciences, Inc.----

Findings Presented at 57th Annual Meeting of the American Academy
of Neurology

Clinical study investigators concluded that tetrabenazine was an
effective and well-tolerated treatment for severe hyperkinetic
movement disorders among children who are resistant to other
medications, according to new data presented today at the 57th Annual
Meeting of the American Academy of Neurology in Miami Beach. Frucht .

stroke wrist

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)